PEDRO
PÉREZ SEGURA
Profesor asociado de Ciencias de la Salud
Hospital General Universitario Gregorio Marañón
Madrid, EspañaPublications en collaboration avec des chercheurs de Hospital General Universitario Gregorio Marañón (21)
2024
2023
-
Expert Consensus: Main Risk Factors for Poor Prognosis in COVID-19 and the Implications for Targeted Measures against SARS-CoV-2
Viruses, Vol. 15, Núm. 7
-
What do patients and oncologists think about the evaluation and management of cancer-related anorexia-cachexia? The Quasar_SEOM study
Clinical and Translational Oncology, Vol. 25, Núm. 12, pp. 3479-3491
2022
-
Do Antiangiogenics Promote Clot Instability? Data from the TESEO Prospective Registry and Caravaggio Clinical Trial
Thrombosis and haemostasis, Vol. 122, Núm. 10, pp. 1653-1661
2021
-
Rationale, design and methodology of TESEO study: a registry of thrombosis and neoplasia of SEOM (Spanish Society of Medical Oncology)
Clinical and Translational Oncology, Vol. 23, Núm. 4, pp. 799-811
2020
-
A phase II randomized, multicenter, open-label trial of continuing adjuvant temozolomide beyond 6 cycles in patients with glioblastoma (GEINO 14-01)
Neuro-oncology, Vol. 22, Núm. 12, pp. 1851-1861
-
A snapshot of cancer-associated thromboembolic disease in 2018–2019: First data from the TESEO prospective registry
European Journal of Internal Medicine, Vol. 78, pp. 41-49
-
TESEO, cancer-associated thrombosis registry from the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology
-
Update of the recommendations for the determination of biomarkers in colorectal carcinoma: National Consensus of the Spanish Society of Medical Oncology and the Spanish Society of Pathology
Clinical and Translational Oncology, Vol. 22, Núm. 11, pp. 1976-1991
2018
-
Delay in starting radiotherapy due to neoadjuvant therapy does not worsen survival in unresected glioblastoma patients
Clinical and Translational Oncology, Vol. 20, Núm. 12, pp. 1529-1537
-
SEOM clinical guideline in nasopharynx cancer (2017)
Clinical and Translational Oncology, Vol. 20, Núm. 1, pp. 84-88
2017
-
FOTROCAN Delphi consensus statement regarding the prevention and treatment of cancer-associated thrombosis in areas of uncertainty and low quality of evidence
Clinical and Translational Oncology, Vol. 19, Núm. 8, pp. 997-1009
-
Peculiarities of the obese patient with cancer: a national consensus statement by the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 19, Núm. 6, pp. 682-694
-
Role of GALNT12 in the genetic predisposition to attenuated adenomatous polyposis syndrome
PLoS ONE, Vol. 12, Núm. 11
2016
-
Bevacizumab and temozolomide versus temozolomide alone as neoadjuvant treatment in unresected glioblastoma: the GENOM 009 randomized phase II trial
Journal of Neuro-Oncology, Vol. 127, Núm. 3, pp. 569-579
-
Phase II trial of irinotecan and metronomic temozolomide in patients with recurrent glioblastoma
Anti-Cancer Drugs, Vol. 27, Núm. 2, pp. 133-137
2015
-
Mammographic density and breast cancer in women from high risk families
Breast Cancer Research, Vol. 17, Núm. 1
-
Obesity as a risk factor in cancer: A national consensus of the Spanish Society for the Study of Obesity and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 10, pp. 763-771
-
Updated guidelines for biomarker testing in colorectal carcinoma: a national consensus of the Spanish Society of Pathology and the Spanish Society of Medical Oncology
Clinical and Translational Oncology, Vol. 17, Núm. 4, pp. 264-273
2012
-
Guidelines for biomarker testing in colorectal carcinoma (CRC): A national consensus of the Spanish Society of Pathology (SEAP) and the Spanish Society of Medical Oncology (SEOM)
Clinical and Translational Oncology, Vol. 14, Núm. 10, pp. 726-739